Macromolecular (pro) drugs in antiviral research

被引:28
|
作者
Smith, Anton A. A. [1 ]
Kryger, Mille B. L. [1 ,2 ]
Wohl, Benjamin M. [1 ,2 ]
Ruiz-Sanchis, Pau [1 ]
Zuwala, Kaja [3 ]
Tolstrup, Martin [3 ]
Zelikin, Alexander N. [1 ,2 ]
机构
[1] Aarhus Univ, Dept Chem, DK-8000 Aarhus, Denmark
[2] Aarhus Univ, iNANO Interdisciplinary Nanosci Ctr, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; STRONGLY INHIBIT AGGLUTINATION; LIVING RADICAL POLYMERIZATION; ANTI-HIV ACTIVITY; POLY-L-LYSINE; INFLUENZA-VIRUS; IN-VITRO; ENVELOPE GLYCOPROTEIN; DEXTRAN SULFATE;
D O I
10.1039/c4py00624k
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Macromolecular (pro) drugs are a sub-discipline of medicinal and polymer chemistries aiming to optimize the delivery of drugs to their site of action. In recent decades, this field of science has undergone a tremendous development, with the soundest achievements registered in the delivery of anticancer drugs. Surprisingly, the development of these tools for applications in antiviral treatment lags significantly behind -despite the fact that the first in vivo successes of polymers in fighting viruses were reported half a century ago. Furthermore, the unique scope and utility of polymers in antiviral research is that macromolecules themselves exhibit highly potent activity against diverse viruses. Herein, in an attempt to revive the research interest in this field, we aim to provide an overview of successes (and failures) of polymers as antiviral agents and macromolecular prodrugs. Specifically, we discuss inhibition of the entry of the virus into mammalian cells by polymers, give an overview of the synthetic schemes applied for the conjugation of drugs to carrier polymers, and also present guidance with regard to potential reporter systems which can be used for the characterization of novel drug delivery systems in virus-free cell cultures.
引用
收藏
页码:6407 / 6425
页数:19
相关论文
共 50 条
  • [1] Glycosilated macromolecular conjugates of antiviral drugs with a polyaspartamide
    Cavallaro, G
    Maniscalco, L
    Caliceti, P
    Salmaso, S
    Semenzato, A
    Giammona, G
    JOURNAL OF DRUG TARGETING, 2004, 12 (9-10) : 593 - 605
  • [2] Antiviral drugs - Breakthrough for HCV research
    Jones, S
    NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (08) : 629 - 629
  • [3] MACROMOLECULAR DRUGS
    FERRUTI, P
    FARMACO-EDIZIONE SCIENTIFICA, 1977, 3 (03): : 220 - 236
  • [4] Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation
    Wohl, Benjamin M.
    Smith, Anton A. A.
    Jensen, Bettina E. B.
    Zelikin, Alexander N.
    JOURNAL OF CONTROLLED RELEASE, 2014, 196 : 197 - 207
  • [5] Advances research in porcine enteric coronavirus therapies and antiviral drugs
    Liang, Jixiang
    Xu, Weihang
    Pan, Xiaoming
    Han, Shiyun
    Zhang, Linwei
    Wen, Hao
    Ding, Mingyue
    Zhang, Wanpo
    Peng, Dapeng
    VETERINARY QUARTERLY, 2024, 44 (01) : 1 - 49
  • [6] Research progress on the direct antiviral drugs for hepatitis C virus
    Gao, Jianjun
    Ju, Chuanxia
    BIOSCIENCE TRENDS, 2017, 11 (01) : 41 - 45
  • [7] ANTIVIRAL DRUGS
    RUBSAMENWAIGMANN, H
    PFUTZNER, A
    BIESERT, L
    IMMUNITAT UND INFEKTION, 1993, 21 (04): : 106 - 110
  • [8] ANTIVIRAL DRUGS
    COQUIN, Y
    REVUE DU PRATICIEN, 1985, 35 (47): : 2867 - 2871
  • [9] ANTIVIRAL DRUGS
    LIU, C
    MEDICAL CLINICS OF NORTH AMERICA, 1982, 66 (01) : 235 - 244
  • [10] Antiviral drugs
    Balfour, HH
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (16): : 1255 - 1268